| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comprehensive view of pregnancy in patients with sickle cell disease in high-income countries: the need for robust data and further decline in morbidity and mortality
|
Joseph, Laure
|
|
|
11 |
1 |
p. e75-e84
|
artikel
|
| 2 |
Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial
|
O'Brien, Sarah H
|
|
|
11 |
1 |
p. e27-e37
|
artikel
|
| 3 |
Changing the paradigm of AML care in India
|
Singh, Amitabh
|
|
|
11 |
1 |
p. e9
|
artikel
|
| 4 |
Correction to Lancet Haematol 2023; 10: e713–34
|
|
|
|
11 |
1 |
p. e10
|
artikel
|
| 5 |
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
|
Kröger, Nicolaus
|
|
|
11 |
1 |
p. e62-e74
|
artikel
|
| 6 |
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?
|
Stahl, Maximilian
|
|
|
11 |
1 |
p. e5-e7
|
artikel
|
| 7 |
Lucrèce Delicat-Loembet: offering hope to young people with sickle cell disease
|
Kirby, Tony
|
|
|
11 |
1 |
p. e11
|
artikel
|
| 8 |
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
|
Garcia-Manero, Guillermo
|
|
|
11 |
1 |
p. e15-e26
|
artikel
|
| 9 |
Oral decitabine plus cedazuridine versus intravenous decitabine
|
de Witte, Theo
|
|
|
11 |
1 |
p. e2-e3
|
artikel
|
| 10 |
Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study
|
Cargo, Catherine
|
|
|
11 |
1 |
p. e51-e61
|
artikel
|
| 11 |
Predicting the progression of patients with CCUS to myeloid neoplasia
|
Groarke, Emma M
|
|
|
11 |
1 |
p. e7-e8
|
artikel
|
| 12 |
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
|
Zeidan, Amer M
|
|
|
11 |
1 |
p. e38-e50
|
artikel
|
| 13 |
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?
|
Boissel, Nicolas
|
|
|
11 |
1 |
p. e13-e14
|
artikel
|
| 14 |
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?
|
Chevallier, Patrice
|
|
|
11 |
1 |
p. e12-e13
|
artikel
|
| 15 |
The dawn of the CRISPR/Cas9 gene therapy era
|
The Lancet Haematology,
|
|
|
11 |
1 |
p. e1
|
artikel
|
| 16 |
Thromboprophylaxis in paediatric acute lymphoblastic leukaemia
|
Athale, Uma H
|
|
|
11 |
1 |
p. e3-e5
|
artikel
|
Tijdschrift beschrijving